Research programme: NY-ESO targeted antibodies - Crystal Bioscience

Drug Profile

Research programme: NY-ESO targeted antibodies - Crystal Bioscience

Latest Information Update: 27 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Crystal Bioscience
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CTAG1B protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 27 Jul 2016 Research programme: NY-ESO targeted antibodies - Crystal Bioscience is available for licensing as of 27 Jul 2016. http://www.crystalbioscience.com/
  • 27 Jul 2016 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top